Mr Steven Newborn > Weil, Gotshal & Manges LLP > Washington DC, United States > Lawyer Profile

Weil, Gotshal & Manges LLP
2001 M STREET, NW, SUITE 600
WASHINGTON, DC 20036
DISTRICT OF COLUMBIA
United States
Steven Newborn photo

Work Department

Antitrust/Competition

Position

Head of Weil’s global Antitrust/Competition practice.

Career

Steve Newborn, Chair of Weil’s global Antitrust/Competition Practice, specializes in ‘bet the company’ mergers and high stakes antitrust litigation for Fortune 100 companies encompassing a wide array of industries and international venues. He has successfully obtained approvals for several hundred transactions, many of which had run into regulatory problems before he was retained. He is ranked by every publication as one of the best in the profession and has been called the “best antitrust lawyer of his generation.” Prior to entering private practice he ran the FTC’s Bureau of Competition merger enforcement program.

Education

Long Island University Brooklyn (BA, 1971); St. John’s University School of Law (JD, 1974).+1 202 682 7005

Lawyer Rankings

United States > Antitrust > Civil litigation/class actions: defense

Counting leading global tech giants, publishers, and pharma corporations among its impressive roster of clients, Weil, Gotshal & Manges LLP excels across all stages of litigation, with a strong track record of securing pre-trial victories as well as defeating class certifications. Former FTC litigation director Steven Newborn, merger review and clearance expert Brianne Kucerik, former FTC assistant director Jeffrey Perry, and Michael Moiseyev, who focuses on cross-border mandates, jointly oversee the ‘excellent’ practice; all four are based in Washington DC. New York’s Eric Hochstadt focuses on class actions and a broad range of other civil antitrust litigation, with a notable emphasis on sports-related cases. The ‘deeply experienced’ Adam Hemlock , also in New York, takes point on cartel matters, amnesty proceedings, and consumer class actions in the electronics and pharma industries.